Hook and thesis
Ultragenyx (RARE) is a classic biotech binary: the shares changed hands around $26.40 after a turbulent stretch driven by a Phase III disappointment for setrusumab and follow-on litigation. The market appears to have overshot on the downside. With two upcoming FDA decisions that can materially re-rate the company, I favor a long-biased, event-driven trade with a clear entry, stop and target.
My thesis is simple: the company already generates recurring revenue from multiple approved rare-disease drugs, trades at a market cap of roughly $2.8 billion and presents asymmetric upside if either FDA outcome goes the company’s way. The downside is significant if the regulatory outcomes disappoint, so the trade must be size-managed and time-boxed to the events.
What Ultragenyx does and why the market should care
Ultragenyx Pharmaceutical is a rare-disease biopharma focused on developing and commercializing therapies for genetic conditions. Its marketed products include Crysvita (for X-linked hypophosphatemia and related disorders), Mepsevii (mucopolysaccharidosis VII), Dojolvi (for long-chain fatty acid oxidation disorders), and Evkeeza (for homozygous familial hypercholesterolemia). Those franchises create a recurring revenue base that tempers binary clinical risk and provides a runway for ongoing R&D.
The market will focus on two things: 1) upcoming FDA decisions tied to late-stage programs, which are binary catalysts that can quickly re-rate the equity, and 2) the steadiness of commercial revenue and operational cash burn while the company executes. For event-driven traders and longer-term investors, the combination of recurring product revenue and a relatively modest market cap makes RARE a compelling candidate for an asymmetric bet around regulatory readouts.
Key financials and positioning
- Current price: $26.40 (previous close $26.86).
- Market capitalization: roughly $2.79 billion.
- Enterprise value: about $2.48 billion with EV/sales around 3.45x and price/sales ~3.63x.
- Reported earnings per share: -$5.94, and free cash flow was negative $489.5 million (most recent data point), indicating continued investment into R&D and commercialization.
- Balance sheet and liquidity signals: current ratio ~1.73 and quick ratio about 1.56. Cash per share reported ~$0.36 (note: operating burn remains material).
Those numbers tell a consistent story: Ultragenyx is not an early pre-revenue biotech. It has marketed products that generate sales and lend resilience, but it is still consuming cash to fund clinical programs. That positions RARE as a hybrid — commercial biotech with binary regulatory events looming. Market cap and EV imply the street is pricing in downside risk, which creates opportunity if one or both regulatory decisions are positive.
Valuation framing
At a market cap near $2.8 billion and EV roughly $2.48 billion, the stock is priced like a company with non-trivial execution risk. Price-to-sales near 3.6x is not cheap for a company burning cash, but you must weigh that against high-margin rare-disease drug sales and potential upside from new approvals. The shares sit well below the 52-week high of $39.89, and the pullback after the Phase III readout and subsequent legal action (a one-day drawdown cited as a ~42% drop following the Phase III announcement) suggests the market may have overshot pessimism into the current price range.
Qualitatively, if one regulatory decision restores confidence in the clinical story for a key program, a re-rating back toward previous multiples (or at least toward the $35–40 range) is plausible. Conversely, if both decisions are negative, valuation could compress further given continued cash burn and legal overhang.
Catalysts
- Two upcoming FDA decisions tied to late-stage assets - these are the primary binary catalysts and can move the stock materially in either direction.
- Quarterly commercial update reflecting trends in Crysvita, Dojolvi, Mepsevii and Evkeeza sales - continued revenue growth would reduce perceived downside risk.
- Any settlement or resolution progress in class-action suits related to setrusumab study results - legal clarity reduces headline risk.
- New regulatory filings or label negotiations that could expand addressable populations for existing therapies.
Technical and sentiment context
Technicals suggest the stock is digesting recent volatility: 10-day SMA is about $25.94, 20-day SMA about $26.57, and 50-day SMA around $27.92. RSI sits near 45, not oversold but not overbought either. Short interest is meaningful and persistent — recent short interest was roughly 15 million shares with days to cover typically in the 7–9 day range, which can amplify moves on favorable news.
Trade plan - actionable
Direction: Long
Entry: $26.40
Target: $35.00
Stop loss: $22.00
Horizon: long term (180 trading days) - I expect this trade to last through the two FDA decisions and into the subsequent re-rating window. The 180 trading day horizon gives time for regulatory timing slips and for the market to digest commercial updates and any legal developments.
Trade sizing: treat this as a high-risk event trade. Limit exposure to a small percentage of risk capital (for example, 1-3% of portfolio). If you get filled at or below the entry and the stock approaches the stop, exit to limit losses. If a favorable decision is announced, consider trimming into strength — the $35 target is a first take-profit area aligned with a partial re-rating toward prior levels.
Why this setup offers asymmetric upside
The asymmetry comes from three facts: 1) Ultragenyx already has commercial revenue, which supports valuation even if one program fails; 2) the market has penalized the shares sharply after the negative Phase III headlines and subsequent legal filings, likely pricing in worst-case scenarios; 3) a single positive FDA decision could unlock a meaningful re-rating given the added revenue and improved clinical credibility.
Risks and counterarguments
- Binary regulatory risk: If the FDA decisions reject the filings or demand additional data, the stock can gap lower well past the stop. Regulatory outcomes are inherently binary and can be decisive.
- Legal overhang: Multiple class-action suits allege misleading statements around setrusumab’s Phase III results. Litigation costs, settlements, or adverse rulings could materially impact equity value and distract management.
- Cash burn and FCF pressure: Free cash flow was negative roughly $489.5 million, which keeps dilution or financing risk on the table if approvals are delayed and revenue ramps slower than expected.
- Commercial execution risk: Even with approvals, competing therapies, payer dynamics, or slower-than-expected adoption could limit upside to valuations implied by the target price.
- Market sentiment and short interest: Elevated short interest can exacerbate downside in a panic sell-off, or conversely accelerate rallies; both increase volatility and trading risk.
Counterargument: The market may already have fully priced in the clinical and legal risks, meaning that even a single positive FDA decision might not push the stock dramatically higher if investors remain skeptical about label, commercial potential, or payer uptake. Additionally, continued negative free cash flow and potential for further dilution could mute a recovery.
What would change my mind
I would become more negative if Ultragenyx reported materially worse-than-expected commercial numbers for its marketed drugs, if free cash flow trends deteriorate further (forcing a dilutive financing at a low share price), or if the FDA decisions come back clearly negative. Conversely, a confirmed positive decision on at least one key program, combined with solid commercial performance, would increase my conviction and push my upside target higher (toward the prior 52-week high).
Conclusion
RARE is an event-driven, high-risk/high-reward trade. At $26.40 the stock offers asymmetric upside into two imminent FDA decisions while still carrying material downside if regulatory or legal outcomes disappoint. For disciplined traders comfortable with biotech binary risk, the long trade with an entry at $26.40, stop at $22.00 and a target of $35.00 over a long-term (180 trading days) horizon provides a clear, balanced way to play the company’s upcoming catalyst window.